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Celiac disease (CD) is a chronic systemic autoimmune 
disorder sustained by an inappropriate response to gluten. 
The term gluten is often used to encompass the prolamins, 
specific storage ethanol-soluble proteins, of wheat, rye 
and barley at the base of the characteristic immune 
response of celiac disease. The development of clinical 
symptoms of CD is a consequence of the encounter 
between an environmental trigger and a genetically 
predisposed host, with the possible participation of other 
environmental cofactors like drugs, intestinal infections or 
infant-feeding practices. Genetically susceptible individuals 
develop an autoimmune injury to the gut, skin, joints, liver, 
brain, heart, uterus and other organs [1]. 
There are at least 50 toxic epitopes in gluten peptides 
exerting citotoxic, immunomodulatory and gut-permeating 
activities, but most of them are digested by gastric, 
pancreatic and intestinal proteases [2]. However, in celiac 
patients, one of these epitopes promotes the release of 
zonulin peptide in small bowel mucosa. Zonulin activates 
an intracellular pathway that ends with the disassembly of 
the tight junction (TJ). This directly affects the opening of 
the paracellular pathway, allowing the toxic 33-mer 
gliadin peptide to make contact with the tissue 
transglutaminase and the antigen-presenting cells in the 
lamina propria [3] generating the immune response. 
CD may affect as many as 1% to 3% of the European 
and North American population [1]. The CD prevalence is 
significantly higher than that recognized 20 years ago; in 
fact, recent studies have demonstrated that the incidence is 
increasing in North America and Europe [4]. A change in 
human genetics is unlikely, because it would take too long 
even in the event that there was an environmental variable 
that exerts a selective pressure. So the high and increasing 
incidence may partly be explained by high physician 
awareness, large-scale efforts to screen at-risk groups 
(such as women and patients with other autoimmune 
diseases) and the introduction of screening diagnostics 
more complete and accurate, such as the anti-endomysial 
antibody and anti-tissue transglutaminase antibody 
serological assay. Ludvigsson et al. [5], in a recent study 
on the US population, proposed an environmental 
exposure cause for the increased incidence of CD in US, 
i.e. the increased consumption, in frequency and amount, 
of gluten in foods available for the US population. 
However, the lack of reliable data on the amount of gluten 
in foods and of data from other countries does not allow 
the reaching of a conclusion. 
Besides CD and wheat allergy, there are other cases of 
gluten reactions in which neither allergic nor autoimmune 
mechanisms are involved. These are generally defined as 
gluten sensitivity (GS) or non celiac gluten sensitivity 
(NCGS), a condition in which symptoms are probably 
triggered by gluten ingestion, in the absence of celiac-
specific antibodies and of classical celiac villous atrophy, 
with variable human leukocyte antigen status and a 
variable presence of first generation anti-gliadin antibodies 
[6]. 
Since the ingestion of gluten is correlated with an 
inflammatory prolonged condition and, in turn, results in a 
malabsorption of essential micronutrients, such as iron, 
zinc, calcium, folic acid and fat-soluble vitamins, the only 
known therapy is a lifelong gluten-free diet (GFD) that 
can lead to a mucosal healing and an improvement in 
pathological symptoms and nutritional status. The GFD 
excludes any products derived from wheat, barley and rye 
grains [7]. Not considering the particular, and not very 
frequent, case of the non responsive celiac patients, the 
elimination of gluten usually induces the clinical 
improvement within days or weeks, even though the 
histological recovery takes months or even years, 
especially in adults, in whom the mucosal recovery may 
also be incomplete [8]. 
Lebwohl et al [9] reported that the gut injury is 
correlated with the prevalence of villous atrophy in 
adulthood and is influenced by the prolonged course of 
symptoms prior to diagnosis, the discontinuous follow-up 
biopsy and a late institution of GFD. Adults and older 
people may have a longer and untreated CD than younger 
and, as a consequence, their gut inflammation and atrophy 
may be more persistent [9]. The persistent pro-inflammatory 
stimuli, related to the prolonged presence of pro-
inflammatory mediators of the innate immune system and 
the prevalence of Th1 cells of adaptive immune system, 
result in a gradual overload of the gut with reactive 
oxidant species that gradually weaken the antioxidative 
defense system [10]. Therefore, such continued pro-
inflammatory stimuli to the intestinal mucosa result in: i) a 
tissue hardly damaged, with a loss of barrier function and 
compartmentalization; ii) a reduction of mucus layer and 
its protective and regulatory functions; iii) an altered 
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exposure and tolerance to sequestered antigens, autoantigenes 
or components of microbiota. 
The identification of intestinal microbiota as a 
prominent environmental factor shaping diverse aspects of 
the intestinal and extra-intestinal health and diseases has 
fueled an intense interest in defining the mechanisms 
underlying host-microbiota interactions [11]. It is well 
known that the human gastrointestinal tract is a complex 
and dynamic environment sheltered by a vast number and 
variety of commensal microorganisms. This balanced 
microecosystem provides the host a natural defense 
against the invasion of potential pathogens. Studies of the 
role of the gut microbiota in CD pathophysiology are still 
in their infancy and to date it is still unclear whether an 
altered microbiota in CD patients could be the cause or the 
consequence of the pathology. De Sousa Moraes et al. [12] 
recently reviewed the main findings on this issue.  
It is hypothesized that the proportion of gram-negative 
and gram-positive bacteria may be of importance in CD 
patients and that gram-negative bacteria in genetically 
susceptible individuals may contribute to the loss of 
tolerance to gluten. Low levels of Lactobacillus and 
Bifidobacterium species in CD children have been 
observed in favor to a major prevalence of pro-
inflammatory gram-negative bacteria, such as 
Bacterioides-Prevotella and Escherichia coli [12]. In 
addition, Bernardo et al [13] have recently suggested that 
in the duodenum of celiac patients with respect to healthy 
controls, independently of interleukin 15 (IL-15) levels or 
of the inflammatory intestinal condition, there is a high 
expression of the IL15-receptor-alpha. Such high 
expression could determine a lower threshold of activation 
of innate immune response in CD predisposed individuals 
with respect to healthy subjects. As a consequence, it 
would be speculated that these individuals could be more 
sensitive to the environmental triggers, such as microbiota 
fragments and metabolites, than healthy ones. 
Considering all the cited studies concerning the 
intestinal dysbiosis [12] and the possible constitutive 
alteration of the innate immune response [13], it might be 
possible that the celiac patient could have alterations that 
may be the basis of inflammatory disorders untreatable 
with just the elimination of gluten from the diet. Reducing 
the inflammatory stress could allow the intestinal tissue to 
recover its barrier function between intestinal lumen and 
submucosal space, thus preventing the food antigens to 
reach the effector cells of the adaptive immune system. 
These suggestions should be considered in the 
development of gluten-free (GF) products. To date, the 
composition of GF products has been formulated with the 
major purpose of eliminating the gluten and overcoming 
the technological gap resulting from its elimination. 
Therefore, in the future, such products should also be 
formulated, for instance, for controlling the intestinal 
dysbiosis and for promoting the balance of intestinal 
microbiota towards gram-positive species and, in turn, the 
inflammatory condition. 
For a variety of reasons, the market for GF products is 
in a continuous expansion. This huge requirement 
determines an increasing demand for GF products with 
sensory and nutritive characteristics suitable for replacing, 
at least partially, the traditional wheat-based products [14]. 
From a technological point of view, gluten is a 
structure-building protein, which contributes to the 
formation of a strong protein network. This confers visco-
elasticity to the dough and allows the wheat flour to be 
processed into a wide range of products. As a consequence, 
the technological process of GF cereal based products 
entails some difficulties. For example, the GF batter and 
dough have been described as being less cohesive and 
elastic than wheat dough, more difficult to handle and as 
having poor gas retention. GF yeast-raised baked goods 
have been portrayed as having a low volume, a pale crust, 
a crumbly texture and other problems that affect the taste 
and acceptability by the consumer [15]. Therefore, 
obtaining high-quality yeast-raised baked goods is a 
technological challenge that leads to the search for 
ingredients, additives and technologies that can improve 
the bread-making performance of GF flour. The 
techniques and the recipes for improving the sensory 
quality of the GF products have been recently reviewed 
[14]. 
From the nutritional point of view, the exclusion of 
gluten does not entail particular problems, being a mixture 
of proteins with a low nutritional and biological value. 
However, its replacement affects the other nutrients in GF 
products, especially in the bread category, such foods 
being poorer in proteins, but richer in total and saturated 
fats when compared with their gluten-containing 
counterparts [16]. In pasta, flours and cereal bars, there are 
some additional nutritional concerns, such as high levels 
of sodium and cholesterol [16]. A recent review from 
Pellegrini and Agostoni [17] also highlights the fact that 
such goods may contain less micro-nutrients with respect 
to the gluten-containing counterparts. Lately, in some GF 
recipes the use of pseudo-cereals and non-conventional 
flours and starches as ingredients to enrich the dough in 
micro-nutrients and fiber has been reported [18]. This 
choice is also due to the market demand arising from the 
consumer’s request for nutritional ingredients in GF 
products. 
A celiac patient, in the context of gluten exclusion, 
should have dietary habits in line with the principles of the 
Mediterranean diet, a healthy and protective food model, 
or one with other dietary regimes promoted by the 
national and international health organizations. A healthy 
dietary pattern is rich in plant foods, such as cereals, fruit, 
vegetables, legumes, tree nuts, seeds and olives, with a 
moderate intake of fish and seafood, eggs and dairy 
products and a low consumption of red meat and other 
processed meats. This pattern ensures an adequate intake 
of macro- and micro-nutrients and bioactive molecules 
that promote health in a general population. However, the 
widespread adherence to the western lifestyle contributes 
to the custom of using convenience foods and meals. 
Calder and colleagues [10] in a work commissioned by 
ILSI Europe on the inflammatory disease process and the 
interaction with nutrition discussed the connection 
between the western lifestyle (urban life, pollution, 
psychological stress, infections, reduced physical activity 
and dietary habits poor in fruit and vegetables and rich in 
nutrient-poor foods containing high levels of sugar and 
saturated fats) and the resulting oxidative stress in the 
body. Moreover, the authors highlighted the negative 
effect that this lifestyle may have on the gut barrier of the 
entire population and the severe implications for people 
who suffer from chronic intestinal diseases, like celiac 
disease. However, the eating of such products is often a 
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choice dictated both by their convenient accessibility and 
the strong desire of the celiac patient for social acceptance 
[19]. Theoretically, to follow a strict GFD is simple, but 
its management is much more difficult. It requires well-
motivated patients, supported by an experienced dietitian, 
family and community. 
Today a celiac patient is prone to include in his or her 
diet industrial GF foods, like bread, pasta, cookies, cereal 
bars, pizza or prepared meals. The major concern about 
those foods is that the food industry still employs 
primarily refined flours and starches from maize and rice, 
which are poor in micro-nutrients, as conventional 
substitutes for wheat flour and it enhances the taste of 
them by the addition of sodium and fats. Nowadays, there 
are some nutrients, such as polyunsaturated fatty acids, 
antioxidant vitamins, polyphenols, prebiotics and 
probiotics, to which the nutritional research is paying 
special attention, exploring also their effect on 
immune/inflammatory markers. In developing GF 
products, the food industry should take into account such 
research. 
An aspect that is becoming extremely relevant is the 
study of the gut barrier integrity and the right balance of 
the gut microbiota. In fact, the question of how we can 
improve the gut barrier function and the gut microbiota, 
not only for healthy people but also for celiac patients, has 
assumed a key role for maintaining human health. The 
research on the modulation of gut barrier integrity and 
permeability by the diet is recently starting and there are 
some dietary factors that have been proposed to improve 
such aspects [20]. Among them, two major factors could 
be identified: i) nutrients/prebiotics; ii) probiotics [20]. 
Some nutrients and non-nutrients might act in an anti-
inflammatory manner by reinforcing the regulatory 
pathways that control the inflammatory responses. 
Polyphenols, prebiotic food components or probiotic 
bacteria might be of great interest as future “therapy” of 
the intestinal barrier-related diseases [20,21]. In this way, 
tailored developed foods might contribute to the 
robustness of homeostatic control and help to reduce the 
risk that the inflammatory response, acute or chronic, 
determines a continuous damage to the gut [10]. 
Recently, some studies on the gut of the celiac patients 
focused on the balance and the composition of the 
intestinal microorganisms and also on the negative effects 
of dysbiosis [22,23] as a consequence of the GFD [12,24]. 
However, to date, there is a lack of consensus about the 
exact bacterial composition in patients with CD [12]. 
Nevertheless, as introduced above, the importance has 
been demonstrated, also for the celiac patients, of the 
presence of Lactobacillus and Bifidobacterium, gram-
positive and anti-inflammatory species, to improve the 
integrity of gut trans-epithelial barrier by i) contrasting the 
colonization, for example, by Escherichia coli or Shigella, 
considered as the pro-inflammatory bacteria, and ii) 
reducing the release of pro-inflammatory cytokines by the 
activated monocytes [12]. However, in the perspective of 
positively modulating the gut microbiota of celiac patients, 
the supplementation of preparations containing probiotics 
currently does not meet the consensus of the scientific 
community and, moreover, the GF foods are not goods 
traditionally functionalized with probiotics. A more 
concrete way for obtaining a correct microorganism 
balance in favor of gram-positive anti-inflammatory 
species should be the introduction of resistant 
polysaccharides from plant foods and the reduction of 
fatty acids in GF foods [25]. 
An aid to reduce the use of fat ingredients rich in 
saturated fatty acids in breads comes from an ancient 
production technique: sourdough fermentation. Sourdough 
is a mixture of lactic acid bacteria (LAB), yeast and flour. 
This technique, applicable to various combinations of 
flour, positively influences all aspects of bread quality: 
texture, aroma, nutritional properties and shelf life. Also 
particularly interesting is the production of a wide variety 
of long chain sugar polymers, called exopolysaccharides 
(EPS), from sucrose during the sourdough fermentation by 
many LAB. Some EPS can improve the GF bread 
technological quality by acting as hydrocolloids and 
potentially its nutritional quality by acting as prebiotics 
and anti-inflammatory and immunomodulatory agents 
[26]. Moreover, due to the presence of such compounds, 
substituting the classic guar gum or hydroxypropyl 
metilcellulose, the GF breads could be perceived as more 
natural by consumers [18]. 
EPS combined with alternative flours, resistant starch 
(RS) and viscose fibers are also studied for their role in 
the glycemic response to GF bakery foods [26]. Although 
these studies need to be deepened, the GF breads with 
sourdough could also be the answer to the demand for 
clean labels, natural products and a reduced use of 
additives [14]. 
EPS, RS and resistant non starch polysaccharides, 
usually defined prebiotics, are considered simpler and 
more effective modulators of the gut microbiota with 
respect to probiotics [27]. These substances, which occur 
naturally in foods or are extracted from natural sources or 
synthesized and added to processed foods, are not, or are 
minimally digested, in the small intestine. They are carried 
on into the large intestine where they are fermented 
selectively from the beneficial bacterial groups, such as 
Bifidobacterium, Lactobacillus and Eubacterium species. 
The metabolites that those beneficial species produce can 
be used as energy source, immune system enhancers or 
facilitators of mineral uptake. In particular, among the 
most represented metabolites, there are short-chain fatty 
acids (SCFAs), such as acetate, propionate, butyrate and 
valerate. These acids can disrupt both the vitality and gene 
expression of pro-inflammatory and pathogenic species or, 
as in the case of butyrate, they could play a particular role 
for maintaining the intestinal barrier integrity by acting on 
the TJ [28]. 
Despite the fact that studies conducted to date concern 
mainly the role of prebiotics in the colon, bacterial species, 
such as Bifidobacterium, Lactobacillus and Eubacterium, 
are also present, though in small amounts, in the small 
intestine. Therefore, it would be reasonable to think that 
foods containing prebiotics might also affect the balance 
of resident microbiota in the small intestine. This 
consideration is supported by the presence of SCFAs in 
the small intestine [29]. 
Food industries already use dietary fibers as ingredients 
in the formulation of GF food, although, at present, 
dietary fibers are mainly used for their technological 
properties, instead of as prebiotics. Therefore, these 
ingredients or the sourdough metabolites (e.g., EPS) 
should be intentionally used in the future formulation of 
GF foods.  
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Although the studies are in their infancy, a microbiota 
imbalance and a pro-inflammatory status in the gut are 
assumable conditions in CD patients, even though on GFD. 
Therefore, in the development of GF foods the goal of 
achieving a healthy gut should be pursued. However, 
further studies are needed to better understand the role of 
prebiotics in the modulation of gut microbiota. Moreover, 
the studies regarding the role of the dietary habits of CD 
patients on the gut microbiota and the effect of dysbiosis 
in modulating the inflammatory stress in the celiac patient 
intestine should be extended. 
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